Myeloma Patients Europe (MPE) held a webinar Minimal Residual Disease (MRD) in myeloma and related diseases given by Paula van Hennik, Committee for Medicinal Products for Human Use (CHMP) member at the European Medicine Agency (EMA). Continue reading
The pharmaceutical company, Karyopharm Therapeutics has announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19 (coronavirus). Continue reading
Myeloma Patients Europe (MPE) will hold a webinar on Minimal Residual Disease (MRD) in myeloma and related diseases on Monday 20 April 2020 from 18:00 – 19:00 CET. Continue reading
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have myeloma and other blood cancers. Continue reading
Myeloma Patients Europe (MPE) held a webinar on big data, the Harmony example given by Ana E. Rodríguez, Institute for Biomedical Research of Salamanca (IBSAL), Spain. Continue reading
The increase in the number of people affected by COVID-19 (coronavirus) has generated great concern, and has forced a number of countries to implement measures in order to stop the spreading of the virus. These measures are, in many countries, very restrictive and can include social distancing and working from home in a situation of self-quarantine or isolation, in order to avoid infection of self, and others. Continue reading
Whilst many people will only get mild to moderate symptoms of COVID-19 (coronavirus), myeloma and AL amyloidosis patients should be extra cautious during the current outbreak. The president of Myeloma Patients Europe (MPE), Hans Scheurer, sends a message to MPE members, myeloma and AL amyloidosis patients. Watch it below: Continue reading
We are seeking a Patient Advocacy Programme Manager to join our growing team! Continue reading
Myeloma Patients Europe (MPE), an European umbrella organisation representing myeloma and AL amyloidosis patient groups, is seeking an experienced Scientific Engagement Manager to develop the scientific and medical strategy of the organisation and to ensure all organisational programmes are underpinned by sound scientific information. Continue reading
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for isatuximab (Sarclisa®). The CHMP recommends this drug in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. Continue reading